Early-stage drug discovery company focused on targets in metabolic diseases and oncology
Investors 1
| Date | Name | Website |
| 16.05.2024 | XGEN VENTU... | xgenventur... |
Mentions in press and media 1
| Date | Title | Description |
| 09.11.2022 | TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Ass... | INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identif... |